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Proteasomal InhibitionThe 26S proteasome is a protease complex that completely degrades substrate
proteins marked with a chain of ubiquitins, but is also able to perform
endoproteolytic cleavage. A new study now demonstrates that regulated
ubiquitin–proteasome-dependent processing ameliorates proteasomal
inhibition.Thorsten Hoppe
The proteasome is essential for
ubiquitin-mediated degradation of
damaged or regulatory proteins [1]. Its
20S core particle is a cylinder formed
by four seven-subunit rings that
contains the proteolytic sites. The
unfolding and translocation of
ubiquitylated substrates into the
hollow 20S particle is catalyzed by two
19S cap structures, one sitting over
each end of the cylinder [2]. This
‘self-compartmentalized’ architecture
of the 26S proteasome ensures
the highly selective nature of the
ubiquitin–proteasome system; only
ubiquitylated proteins are allowed to
reach the active sites within the inner
20S core and get completely cleaved
into small peptides [3].
It has been shown recently that the
proteasome does not always fully
degrade substrate proteins, with
endoproteolytic cleavage by the
proteasome sometimes initiating
processing of dormant precursor
proteins. These processing events
might arise from internal cleavage of
polypeptide loops that enter the20S core particle of the proteasome [4].
Such an endoproteolytic cut could be
a general mechanism for proteasomal
degradation, since substrate turnover
is often associated with the
appearance of cleavage products [5].
These by-products are usually
degraded with a different half-life
comparedwith the particular full-length
proteins. However, the specific
topology of protein domains and/or
protective binding partners can
prevent proteasomal degradation of
certain biologically active protein
fragments.
Examples of substrates of this
regulatory proteasomal cleavage
mechanism — termed regulated
ubiquitin–proteasome-dependent
processing (RUP) — are the
transcription factors NF-kB, Spt23p
and Mga2p [6,7]. NF-kB governs
immune and inflammatory responses
linked to apoptosis and cancer.
Ubiquitylation of its inactive precursor,
p105, results in proteasomal
degradation of the carboxy-terminal
region and release of the stable p50
subunit of NF-kB [6]. Spt23p and
Mga2p are distant NF-kB homologuesthat control fatty acid metabolism in
the budding yeast Saccharomyces
cerevisiae. Similar to NF-kB, both
are produced as dormant precursors
(p120) but are anchored to the
endoplasmic reticulum (ER).
Intriguingly, processing of the p120
forms depends on the composition
of the ER membrane and liberates the
active amino-terminal transcription
factor domain p90 when unsaturated
fatty acids are needed [7].
These data provide evidence that
both conformational and functional
properties of the precursor proteins
influence the efficiency of RUP.
Conversely, little is known about
the impact of the proteasome in the
coordination of this unconventional
cleavage process with physiological
demands. A new study by the Goldberg
laboratory, published in a recent issue
of Current Biology, now highlights
a fascinating role of RUP that links
processing of the transcription factor
Nrf1 to proteasomal activity and vice
versa [8].
In this new work, the authors
addressed the previously reported,
counterintuitive observation that
pharmacological inhibition of the 26S
proteasome often results in enhanced
proteasomal activity [9]. Aside from
its use as a tool to reveal cellular
functions, the proteasomal inhibitor
bortezomib (BTZ) is successfully used
in the treatment of multiple myeloma,
a cancer of antibody-generating
plasma cells [10]. However, increased
expression of 26S subunits in
response to BTZ treatment provides
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Figure 1. A feedback circuit coordinates proteasomal activity with proteolytic activation of the
transcription factor Nrf1.
The 85 kDa (p85) inactive Nrf1 precursor (red) is inserted into the ER with the carboxy-terminal
domain facing the cytosol. At high levels of fully functional 26S proteasomes (dark grey),
ubiquitylated p85 is completely degraded into small peptides (red balls) (1). In contrast,
reduced proteolytic capacity of the 26S proteasome (light grey) caused by drug treatment
or unfavorable physiological conditions instigates an endoproteolytic cleavage of Nrf1 and
release of the 75 kDa (p75) fragment (2). The active p75 form of the transcription factor
then migrates into the nucleus and activates the transcription of 26S proteasomal genes
and the ubiquitin-selective chaperone p97. This feedback response mechanism results in
enhanced amounts of active proteasomes, which support complete degradation of Nrf1 (1)
and consequently terminates RUP (2). The ubiquitylation of Nrf1 is mediated by the E3
enzymes Hrd1, Fbw7, and b-TRCP, although regulatory inputs are not yet known. p97 might
be involved in the mobilization process that liberates the p75 fragment from the ER
membrane.
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that often supports drug resistance and
survival of cancer cells. To unravel this
problem, Sha and Goldberg [8] focused
on the central role of the transcription
factor Nrf1, which is known to bind
many promoters of 26S proteasomal
genes [11,12]. In contrast to its
homolog Nrf2, Nrf1 induces the
expression of all 26S subunits upon
treatment with the proteasome
inhibitors BTZ, MG132, MG262, or
epoxomicin [12]. Conversely, cancer
cells lacking Nrf1 are less resistant
against proteasomal inhibition,
suggesting a key role for Nrf1 in
the paradoxical upregulation of
proteasome activity in response
to drug-mediated proteasomal
inhibition.In this context it is interesting to note
that Nrf1 protein levels are regulated
by ubiquitin-mediated degradation
dependent on the E3 ubiquitin ligase
enzymes Hrd1, Fbw7, and b-TRCP
[12–14]. Thus, increased proteasomal
gene transcription caused by drug
treatment could be explained by
stabilization of the Nrf1 protein.
However, this simplified model is not
compatible with several findings.
First, Nrf2 is similarly regulated by the
ubiquitin–proteasome system but has
not been implicated in proteasomal
drug resistance [15]. Second, the new
study by Sha and Goldberg [8] shows
that high concentrations of
proteasomal inhibitors block the
induction of 26S subunits in contrast
to low concentrations. Third, Nrf1 isattached to the ER membrane and
release of the transcription factor
requires proteolytic processing [16].
To pin down the concentration-
dependent nature of proteasomal
inhibition, Goldberg and colleagues
[8] suggested that RUP could be
a candidate mechanism responsible
for Nrf1 activation. Indeed,
they convincingly showed
proteasome-dependent cleavage
of the membrane-bound p85 Nrf1
precursor into the active p75 form.
Intriguingly, Nrf1 processing only
occurred when the 26S proteasome
was partially active, and this
processing was blocked upon
complete proteasomal inhibition.
This correlation between proteasomal
activity and Nrf1 activation provides
a clear explanation for how drug
treatment might result in increased
26S gene expression. In contrast to
complete degradation of ubiquitylated
Nrf1, partially inhibited 26S
proteasomes with limited proteolytic
activity are inefficient in complete
Nrf1 turnover and instead release
the cleaved Nrf1 p75 fragment,
which activates transcription in the
nucleus. A subsequent increase in
proteasomal capacity might terminate
the upregulation of 26S subunits
by degradation of the active p75 formof
Nrf1 (Figure 1). This elegant response
mechanism allows cancer cells to
survive drug treatment by increasing
the amount of active 26S proteasomes.
In regard to cancer therapy, this
exciting study reveals a new twist for
the pharmacological treatment of
multiple myeloma. As shown here, the
efficiency of proteasomal inhibition can
be monitored using Nrf1 processing
as a biomarker, which might help in
optimizing case-specific medication
protocols. In contrast to cancer
treatment, certain diseases and
physiological conditions would benefit
from an improved performance of
the 26S proteasome. For example,
overexpression of the 19S cap subunit
RPN-6/PSMD11 results in enhanced
stress resistance and longevity both in
Caenorhabditis elegans and embryonic
stem cells [17]. Further knowledge of
the regulation of Nrf1 processing would
provide new ways to antagonize the
age-related decline in proteasomal
capacity that is often associated with
neurodegenerative diseases [18].
Given the current view of how
proteasomal impairment contributes
to the aging process, it would be
Dispatch
R695interesting to learn more about the
physiological role of Nrf1 processing
and the regulation of RUP under
tissue-specific and stress-related
conditions. The activation of Nrf1 is
reminiscent of Spt23p processing
in yeast, which also involves the
ubiquitin-selective chaperone
Cdc48p/p97 [19,20]. Mechanistically,
however, it expands the role of RUP
by showing that it also acts as a
feedback circuit that provides intensive
crosstalk between the proteasome
and its substrate. Given the growing
list of identified substrates,
proteasomal cleavage by RUP
might be more common than initially
expected and could lead to additional
surprises.
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Grow ApartAs genomes evolve, proteins with novel functions arise primarily from gene
duplication and divergence events. A new study identifies several molecular
mechanisms by which related transcription factors diverge over time to control
new sets of target genes and novel cellular functions.Victoria M. Blake and Scott Barolo*
Transcriptional regulation is the
primary mechanism by which cells
control the expression of their genes.
Regulatory proteins called
transcription factors bind to short
sequences of genomic DNA, recruiting
enzymatic co-factors to activate or
repress the expression of nearby
genes. Transcription factors can be
grouped into families with related
DNA-binding domains, but with diverseregulatory functions and distinct sets of
target genes, indicating that novel
transcription factors are born in a
process of gene duplication and
divergence. Although we can identify
and date gene duplication events by
comparing genomic sequences, we
lack a clear picture of how duplicate
proteins diverge functionally over time.
Learning how regulatory proteins
acquire new molecular functions is
essential for understanding how
organisms adapt to new biologicalniches. A new study by Sandy Johnson
and colleagues [1] shows how a
family of duplicated transcription
factors has diverged to play multiple
roles in the biology of the yeast
Candida albicans.
When a transcription factor-
encoding gene undergoes a complete
duplication event, the two resultant
identical copies will not be maintained
in the genome for long unless they
diverge such that each sister gene has
at least one non-redundant function.
This can occur by subfunctionalization,
as in the case of the gene encoding
the vertebrate transcription factor
Engrailed-1. This gene exists in two
copies in the zebrafish genome, each
performing a subset of the functions of
the ancestral engrailed-1 gene [2];
a similar story has ben reported for
two fish paralogs of pax6 [3]. Another
type of divergence, known as
